Utility of a Circulating NET mRNA Gene Signature for Defining Bronchopulmonary Neuroendocrine Neoplasia and Evaluating Disease Progression

#1883

Introduction: Bronchopulmonary NETs (BPNETs) exhibit indolent to aggressive behavior. Imaging, histology and biochemistry are limited in accurately defining malignancy or progression. A blood based NET multigene test is effective in diagnosing GEP-NET progression and therapy response.

Aim(s): Assess the efficacy of NETest in BPNET diagnosis and identification of progressive disease.

Materials and methods: Material: BPNETs: (n=108), controls (n=90), COPD (n=18) and lung cancers (n=12). Measurements: NETest (+ve >14%) by qPCR; CgA by ELISA (normal <109ng/ml); disease status by imaging. Carcinoids were typical TC: n=64, atypical AC: n=44. Clinico-histological groups were AC/SD or AC/PD; TC/SD or TC/PD by RECIST. Progressive disease (PD): 43% AC and 23% TC. Analysis: 2-tailed Mann-Whitney U-tests and ROC-statistics.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Kidd M

Authors: Lewczuk A, Chung K, Kolasińska-Ćwikła A, Ćwikła J, Kidd M,

Keywords: NET,